Loyal appoints Blake Scholl to its board of directors


Scholl brings extensive entrepreneurial experience and technical innovation to help Loyal deliver world’s first FDA-approved longevity drug

Blake Scholl

Photo provided by Loyal

Loyal—a biotech company developing drugs intended to extend the healthy lifespan of dogs—announced today that Blake Scholl has joined as an independent director.1 Scholl brings more than 20 years of successful startup, technical, and commercial experience to Loyal as the company progresses towards FDA approval and bringing their first dog aging drugs to vets and pet parents, the company says.

Scholl is the founder and CEO of Boom Supersonic, a company building the what they claim will be the world’s fastest airliner. He has also held leadership roles at Amazon and Groupon and co-founded mobile technology startup Kima Labs.

“I’m extremely excited that Blake is joining Loyal’s Board. Blake is fascinated with longevity science, has a strong passion for tackling big, important problems, and has invaluable experience bringing entirely new products to consumers,” said Loyal CEO and founder, Celine Halioua. “I look forward to learning from and working with Blake.”

“Time is one of the most valuable commodities we have, which is why I’m inspired by Loyal’s mission to extend the time we have with our best friends, and increase their healthspan,” said Scholl. “I’m excited to contribute my experience to their efforts.”

Scholl’s appointment comes after key company milestones in the last year, including administering the first aging drug to a companion dog—Josie, a 7-year-old Mastiff—and completing canine efficacy studies for both of its drug programs: LOY001, intended for lifespan extension for large dogs, and LOY002, intended for lifespan extension for old dogs of any size. Loyal also recently concluded its X-Thousand Dogs Study,2 the largest dog epigenetics study in history, one of many efforts to quantify the processes of pathological versus healthy aging.

Loyal is currently recruiting veterinary practices to participate in its pivotal study for LOY-002.3


  1. Loyal appoints Blake Scholl to its Board of Directors. News release. Businesswire. February 15, 2023. Accessed February 16, 2023. https://www.businesswire.com/news/home/20230215005837/en/Loyal-Appoints-Blake-Scholl-to-its-Board-of-Directors
  2. Join the largest dog epigenetics study ever conducted. Loyal. Accessed February 16, 2023. https://loyalfordogs.com/x-thousand
  3. Help us help you help dogs. Loyal. Accessed February 16, 2023. https://loyalfordogs.com/for-vets
Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.